Cheplapharm
AstraZeneca jettisons two heart drugs to Cheplapharm in $400m deal
October 30, 2020Manufacturing and Production, Medical Communications, Sales and Marketing AstraZeneca, Cheplapharm
AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand …
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
September 8, 2020Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma
Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …
AstraZeneca jettisons European heart drug rights for $210m
July 24, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma
AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
